Immunology / Virology & Vaccines

#Covid variants #Covid-19 #Immunology / Virology & Vaccines

New data on antiviral efficacy against SARS-CoV-2 variants  

Marinomed Biotech, an Austrian biotech company, has announced results of the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the Delta variant. This has been published in the International Journal of Molecular Sciences.   Collaboration   The peer-reviewed study is… Read More

#Covid-19 #News #Trending News

#Cancer research #Covid variants #Covid-19 #Immunology / Virology & Vaccines #Tumours

Third Covid-19 vaccine boosts immunity for most cancer patients  

According to new results published as a correspondence in Cancer Cell, nearly 100% of cancer patients with solid tumours have antibodies effective against the Delta variant after a third dose of Covid-19 vaccine.  What does this mean?  The new findings highlight a proportion of patients with blood… Read More

#News

#Covid-19 #Healthcare #Immunology / Virology & Vaccines #Public health

European Commission authorises Novavax Covid-19 vaccine

Novavax has been granted conditional marketing authorisation by the European Commission (EC) for Nuvaxovid Covid-19 vaccine.  Context  The vaccine is for active immunisation to prevent Covid-19 caused by SARS-CoV-2 in individuals 18 years of age and older and the authorisation follows the European Medicines Agency’s (EMA) Committee for Medicinal… Read More

#Covid-19 #News #Trending News

#Funding #Immunology / Virology & Vaccines #Life sciences #Research

£50m funding for new vaccine research building at Oxford University 

Oxford University has announced a £50 million funding commitment from Serum Life Sciences to establish The Poonawalla Vaccines Research Building at the University of Oxford.  What will it do?  The Poonawalla Vaccines Research Building will share infrastructure and support facilities with Oxford University Pandemic Sciences… Read More

#News

#Covid-19 #Healthcare #Immunology / Virology & Vaccines #Public health #Research

NIH scientists urge pursuit of universal coronavirus vaccine 

Physician-scientists of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have published a paper in The New England Journal of Medicine which suggests that in order to counter future coronavirus outbreaks, the global scientific and medical research community should focus… Read More

#News #Trending News

#Antivirals #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer Covid pill effective against severe disease 

Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).   The results   These results show that  Paxlovid significantly reduced the… Read More

#Covid-19 #News #Trending News

#Covid variants #Covid-19 #Immunology / Virology & Vaccines #Omicron

Vaccines induce fewer neutralising antibodies against Omicron

Researchers from the University of Oxford have analysed the impact of the Omicron Covid-19 variant of concern on one of the immune responses generated by vaccination.  The study  Using blood samples from individuals who had previously received two doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines as part… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Plant-based

First plant-based Covid-19 vaccine promising says Medicago and GSK

Results from the Phase III placebo-controlled efficacy study of Medicago’s plant-based Covid-19 vaccine candidate in combination with GlaxoSmithKline’s pandemic adjuvant have shown positive results. Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants, unlike most published Phase III efficacy trials for currently licensed Covid-19 vaccines that were conducted… Read More

#Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Drug discovery #Immunology / Virology & Vaccines #Omicron

Preclinical data of drug demonstrates protection against Omicron 

Following the approval of GlaxoSmithKline (GSK) and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), the companies have announced an update, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.  … Read More

#Covid-19 #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Omicron #Therapeutics

Breakthrough: New drug for Omicron and coronavirus strains 

Infex Therapeutics scientists have announced a breakthrough in laboratory trials of a new drug to treat Covid-19 and new variants of the disease, such as the Omicron variant.   Infex’s COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such,… Read More

#Covid-19 #News #Trending News

#Biotechnology #Covid-19 #Drug discovery #Immunology / Virology & Vaccines

Covid-19 treatment cuts hospitalisation and death by 79% 

The Medicines and Healthcare products Regulatory Agency (MHRA), in the UK, has approved GSK and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate Covid-19 infection who are at an increased risk of developing severe… Read More

#Covid-19 #News #Trending News

#Biotechnology #Drug development #Immunology / Virology & Vaccines #Microbiome #R&D

Sanofi acquisition is move for acne vaccine candidate 

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline.  What is ORI-001?  ORI-001 is a therapeutic vaccine candidate for acne vulgaris based… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna announces strategy to address Omicron SARS-CoV-2 variant 

Moderna has announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.   What is Omicron?  The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen… Read More

#Covid-19 #News #Trending News

#Biopharmaceuticals #Drug development #Drug discovery #Immunology / Virology & Vaccines #In vivo

Agreement to develop vaccines against cancer and infectious diseases 

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Read More

#News